Opdivo and chemotherapy combo increases survival in lung cancer patientsLung cancer drug Opdivo administered with chemotherapy has been shown to boost survival rates in patients with resectable Share XOpdivo and chemotherapy combo increases survival in lung cancer patientshttps://pharmaphorum.com/news/opdivo-chemotherapy-combo-increases-survival-lung-cancer-patients/
BMS strikes back against Merck in EU oesophageal cancer marketMerck & Co’s Keytruda become the first cancer immunotherapy to be approved as a first-line oesophageal cancer treatment Share XBMS strikes back against Merck in EU oesophageal cancer markethttps://pharmaphorum.com/news/bms-strikes-back-against-merck-in-eu-oesophageal-cancer-market/
Scotland backs Cabometyx combo for kidney cancer, amid stalled NICE reviewPatients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb’s immunotherapy Opdivo Share XScotland backs Cabometyx combo for kidney cancer, amid stalled NICE reviewhttps://pharmaphorum.com/news/scotland-backs-cabometyx-combo-for-kidney-cancer-amid-stalled-nice-review/
BMS gets FDA nod for Opdivo as first adjuvant bladder cancer therapyBristol Myers Squibb has scored a win in its drive to get Opdivo into earlier lines of cancer Share XBMS gets FDA nod for Opdivo as first adjuvant bladder cancer therapyhttps://pharmaphorum.com/news/bms-gets-fda-nod-for-opdivo-as-first-adjuvant-bladder-cancer-therapy/
GSK claims broader ’tissue-agnostic’ label for PD-1 drug JemperliThe FDA has approved GlaxoSmithKline’s latecomer PD-1 inhibitor Jemperli for a second use that will significantly extend the Share XGSK claims broader ’tissue-agnostic’ label for PD-1 drug Jemperlihttps://pharmaphorum.com/news/gsk-claims-broader-tissue-agnostic-label-for-pd-1-drug-jemperli/
BMS claims first EU okay for adjuvant oesophageal cancer immunotherapyBristol-Myers Squibb is in a battle with Merck & Co for position in the upper gastrointestinal cancer immunotherapy Share XBMS claims first EU okay for adjuvant oesophageal cancer immunotherapyhttps://pharmaphorum.com/news/bms-claims-eu-okay-for-opdivo-in-adjuvant-oesophageal-cancer/
BMS pulls speedy Opdivo approval for liver cancer in USBristol-Myers Squibb has withdrawn its US marketing approval for PD-1 inhibitor Opdivo as a second-line, single-agent treatment for Share XBMS pulls speedy Opdivo approval for liver cancer in UShttps://pharmaphorum.com/news/bms-pulls-speedy-opdivo-approval-in-liver-cancer-in-us/
Keytruda beats Opdivo to first-line oesophageal cancer OK in EuropeMerck & Co’s Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer Share XKeytruda beats Opdivo to first-line oesophageal cancer OK in Europehttps://pharmaphorum.com/news/keytruda-beats-opdivo-to-first-line-oesophageal-cancer-ok-in-europe/
Keytruda should lose stomach cancer indication, says ODACThe FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted to strip Merck & Co’s Keytruda of its accelerated Share XKeytruda should lose stomach cancer indication, says ODAChttps://pharmaphorum.com/news/keytruda-should-lose-stomach-cancer-indication-says-odac/
